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VARYING RATES OF CLOSTRIDIUM DIFFICILE–
ASSOCIATED DIARRHEA AT
PREVENTION EPICENTER HOSPITALS
SeJean Sohn, MPH; Michael Climo, MD; Daniel Diekema, MD; Victoria Fraser, MD; Loreen Herwaldt, MD; Susan Marino, MS, CIC;
Gary Noskin, MD; Trish Perl, MD, MSc; Xiaoyan Song, MD, MS; Jerome Tokars, MD, MPH; David Warren, MD, MPH;
Edward Wong, MD; Deborah S. Yokoe, MD, MPH; Theresa Zembower, MD; Kent A. Sepkowitz, MD, for the Prevention Epicenter Hospitals

ABSTRACT

BACKGROUND: Clostridium difﬁcile–associated diarrhea (CDAD) causes substantial healthcare-associated morbidity. Unlike other common healthcare-associated pathogens,
little comparative information is available about CDAD rates in
hospitalized patients.
OBJECTIVES: To determine CDAD rates per 10,000 patientdays and per 1,000 hospital admissions at 7 geographically diverse
tertiary-care centers from 2000 to 2003, and to survey participating
centers on methods of CDAD surveillance and case deﬁnition.
METHODS: Each center provided speciﬁc information
for the study period, including case numbers, patient-days, and
hospital characteristics. Case deﬁnitions and laborator y diagnoses of healthcare-associated CDAD were determined by each
institution. Within institutions, case deﬁnitions remained consistent during the study period.
RESULTS: Overall, mean annual case rates of CDAD were

12.1 per 10,000 patient-days (range, 3.1 to 25.1) and 7.4 per 1,000
hospital admissions (range, 3.1 to 13.1). No signiﬁcant increases
were observed in CDAD case rates during the 4-year interval, either
at individual centers or in the Prevention Epicenter hospitals as a
whole. Prevention Epicenter hospitals differed in their CDAD case
deﬁnitions. Different case deﬁnitions used by the hospitals applied
to a ﬁxed data set resulted in a 30% difference in rates. No associations were identiﬁed between diagnostic test or case deﬁnition used
and the relative rate of CDAD at a speciﬁc medical center.
CONCLUSIONS: Rates of CDAD var y widely at tertiar ycare centers across the United States. No signiﬁcant increases
in case rates were identiﬁed. The var ying clinical and laborator y
approaches to diagnosis complicated comparisons between hospitals. To facilitate benchmarking and comparisons between institutions, we recommend development of a more standardized
case deﬁnition (Infect Control Hosp Epidemiol 2005;26:676-679).

Clostridium difﬁcile–associated diarrhea (CDAD)
causes substantial healthcare-associated morbidity in many
hospitals. Patients who acquire CDAD require antibiotic
therapy, contact isolation, and prolonged hospitalization and
have a 20% rate of recurrence.1,2 CDAD also imposes a signiﬁcant ﬁnancial burden on healthcare institutions, with an
estimated cost of $1.1 billion per year in the United States.3
In addition, according to the Centers for Disease Control
and Prevention (CDC), the annual rate of healthcare-associated CDAD has increased in recent years.4-6
Unlike other common healthcare-associated pathogens, such as methicillin-resistant Staphylococcus aureus and
vancomycin-resistant Enterococcus, there is little comparative information available about CDAD rates in hospitalized
patients. Such data may be helpful for hospitals seeking to evaluate the effectiveness of their infection control and prevention
programs and to benchmark their rates against national data.

To address the lack of comparative data, we determined the range of CDAD rates at Prevention Epicenter hospitals during the 4-year period from January 1, 2000, to December 31, 2003. In addition, these hospitals were surveyed
on their methods of CDAD surveillance and case classiﬁcation. The Prevention Epicenter is a consortium of seven academic medical centers funded by the CDC to address areas
relevant to infection control and quality promotion.
METHODS
Each Prevention Epicenter hospital provided speciﬁc
information for the study period, including case numbers,
patient-days, and hospital characteristics. All hospitals deﬁned CDAD as a positive laboratory test result for a hospitalized, acute care patient with symptoms. Deﬁnition of symptoms ranged from physician designation of diarrhea alone
to the full deﬁnition of the National Nosocomial Infections
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TABLE 1
ANNUAL CLOSTRIDIUM DIFFICILE INCIDENCE RATES AND PERCENT CHANGE PER 10,000 PATIENT-DAYS AND PER 1,000
ADMISSIONS
2000

2001

2002

2003

Mean

Annual %
Change

Rate per 10,000 patient-days

25.0

19.5

32.6

23.0

25.1

2.69

Rate per 1,000 admissions

13.7

9.8

16.9

12.0

13.1

1.48

Rate per 10,000 patient-days

5.9

5.8

5.7

5.5

5.7

-2.22*

Rate per 1,000 admissions

3.5

3.4

3.3

2.4

3.1

-10.33

Rate per 10,000 patient-days

4.0

5.9

3.0

4.2

4.3

-5.26

Rate per 1,000 admissions

4.0

5.2

2.6

3.4

3.8

-10.95

Rate per 10,000 patient-days

9.2

9.9

7.1

8.7

8.7

-4.75

Rate per 1,000 admissions

6.7

6.9

4.9

5.9

6.1

-7.12

Rate per 10,000 patient-days

22.0

16.0

20.0

20.9

19.7

0.78

Rate per 1,000 admissions

8.8

6.5

4.6

8.1

7.8

-0.99

Rate per 10,000 patient-days

3.7

1.9

3.5

3.4

3.1

4.40

Rate per 1,000 admissions

5.4

2.7

5.2

5.1

4.6

5.01

Rate per 10,000 patient-days

14.2

12.5

14.6

14.0

13.8

1.09

Rate per 1,000 admissions

9.6

8.7

9.9

9.5

9.4

1.10

Rate per 10,000 patient-days

12.3

10.8

13.2

12.2

12.1

-0.53

Rate per 1,000 admissions

8.0

6.7

8.0

7.1

7.4

-3.29

Hospital A

Hospital B

Hospital C

Hospital D

Hospital E

Hospital F

Hospital G

Overall

*The annual percent change differs from 0 to a statistically signiﬁcant degree (two-sided P < .05).

Surveillance System for nosocomial gastroenteritis with previous antibiotic exposure. Diagnostic tests differed among
the various hospitals. Enzyme immunoassay (EIA) testing
for toxins A and B was used by four centers; each of the remaining three centers used cytotoxicity assay, EIA for toxin
A, or EIA for toxin B. One hospital switched in 2002 from
cytotoxicity assay to EIA for toxins A and B, whereas another
switched in 2003 from EIA for toxins A and B to cytotoxicity
assay.
Prevention Epicenter hospitals were surveyed regarding their criteria for classifying CDAD cases. Relevant variables
included the length of time between patient admission and
the collection of incident diagnostic specimens; consideration
of hospital exposure prior to collection of positive specimens;
the interval between a previous hospitalization and the point at
which CDAD was diagnosed; deﬁnition of recurrent cases and
second incident cases; and categorization of outpatient cases.

The annual percent change was estimated by ﬁtting
a least squares regression line to the natural logarithm of
the rate using calendar year as a regressor variable (model:
y = mx + b, where y = ln [rate] and x = calendar year). The estimated annual percent change is equal to 100  (em - 1). The
null hypothesis of the annual percent change being equal to
0 (ie, no increase or decrease in the rate) was tested. The
hypothesis test statistic uses the t distribution of m ÷ SEm,
where SE is the standard error of m and the number of degrees of freedom is equal to the number of calendar years minus 2.7 Data processing and analyses were performed using
SPSS software (version 10.0; SPSS, Inc., Chicago, IL).
RESULTS
The Prevention Epicenter hospitals comprise 5,300
beds with 1.3 million annual patient-days. Approximately
1,750 cases of CDAD occur in the Prevention Epicenter
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TABLE 2
CLOSTRIDIUM DIFFICILE CASE DEFINITION COMPONENTS
Hospital A

Hospital B

Hospital F

Hospital G

Prior to 5/02,
cytotoxicity assay; after 5/02,
EIA for toxins
A and B

Cytotoxicity assay for toxin B

EIA

EIA

EIA and
culture on
CCFA

EIA for toxin A

Cytotoxicity
assay for
toxin B

Hours after admission

> 48

> 48

> 48

> 48

> 48

> 48

 72

Days from previous
discharge date

 60 for oncology patients
only

 30 and no pre-  30
vious positive
assay in 6 mo

NA*

 14

3

NA*

Yes

Yes

Yes

Yes

Yes

Yes

No

> 60 d

> 6 mo

> 30 d with
resolution of
symptoms

Different calendar year

Asymptomatic
period

Asymptomatic
period and no
therapy for 72 h

NA

Yes, if  30
d since last
discharge

No

No

No

Yes, if  3 d
since last discharge

No

Diagnostic test

Hospital C

Hospital D

Hospital E

Criteria for
healthcare-associated cases

“Recurrent” cases
counted as incidents
Time between cases

Outpatient cultures in- No
cluded in healthcareassociated rate

EIA = enzyme immunoassay; CCFA = cycloserine–cefoxitin–fructose agar; NA = not applicable.
*Prior hospital admissions not accounted for.

hospitals each year, for mean annual rates of 12.1 cases per
10,000 patient-days (mean range, 3.1 to 25.1) and 7.4 cases
per 1,000 admissions (mean range, 3.1 to 13.1). During the
4-year period, no signiﬁcant changes in C. difﬁcile rates
were seen for the Prevention Epicenter hospitals collectively or by individual medical centers, with one exception.
Hospital B experienced an annual percent change of -2.22
in the CDAD rate per 10,000 patient-days that was statistically signiﬁcant (Table 1). No associations were identiﬁed
between the diagnostic test or case deﬁnition used and the
relative rate of CDAD per medical center.
Prevention Epicenter hospitals differed in their case
deﬁnitions of healthcare-associated disease. Six centers considered a case to be healthcare associated if the incident diagnostic specimen was collected more than 48 hours after patient
admission; one center required the specimen to be obtained at
least 72 hours after admission (Table 2). The Prevention Epicenter hospitals also were not in agreement about whether
a recent hospitalization should be given consideration when
classifying a CDAD case as healthcare associated. Only ﬁve
of the seven hospitals accounted for prior hospital admissions.
Furthermore, the interval from a previous discharge to the
start of symptoms was not uniform across institutions, ranging from 3 to 60 days. The deﬁnition of recurrent cases varied
widely among the individual Prevention Epicenter hospitals
and only some of the hospitals included outpatient cases in
overall healthcare-associated rates (Table 2).
To examine how extensively case deﬁnition might affect case rates, chart reviews were performed for all incident

cases of CDAD at one Prevention Epicenter hospital during
the 2-year period from January 1, 2002, to December 31, 2003
(n = 370).8 Six different deﬁnitions of healthcare-associated
CDAD were applied to this cohort and the resultant case
numbers and rates were determined (Table 3). When the
strictest deﬁnition of healthcare-associated disease (a positive test specimen collected 3 or more days after admission)
was applied, the rate was 8.67 per 10,000 patient-days. When
more inclusive criteria were used (a positive test result 3 or
more days after admission or a previous hospitalization within
30 days of the ﬁrst positive test result), the rate increased to
10.45 per 10,000 patient-days. With even more inclusive criteria (a positive test result more than 2 days after admission or
a previous hospitalization within 30 days of the ﬁrst positive
test result), the rate rose to 11.33 per 10,000 days. Thus, the
different deﬁnitions of healthcare-associated CDAD used by
the Prevention Epicenter hospitals applied to a ﬁxed data set
resulted in a 30% difference in rates. Although these differences in deﬁnitions did not explain the wide variation of rates
among the Prevention Epicenter hospitals, the variability in
deﬁnitions complicates benchmarking.
DISCUSSION
In contrast to a recent report from the CDC that
evaluated an earlier time period, we did not ﬁnd signiﬁcant
increases in CDAD case rates during our 4-year interval
either at individual centers or in the Prevention Epicenter
hospitals collectively.5,6 These discrepant ﬁndings may be
the result of differing methodologies. The CDC reports
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calculated C. difﬁcile rates using the International Classiﬁcation of Diseases, 9th revision, code diagnoses per discharge, an approach that is inﬂuenced by additional factors
not reﬂected in rates calculated using only laboratory and
clinical hospital data. Alternatively, the hospital sample in
this report may not be large enough to detect a national
trend.
Direct comparisons among the Prevention Epicenter
hospitals were hampered by several factors. First, the diagnostic tests used by the hospitals varied. No studies to date
have shown that the use of different diagnostic tests for C.
difﬁcile has resulted in signiﬁcant differences in CDAD rates.
However, depending on the clinical and laboratory criteria
used for the CDAD case deﬁnition, the sensitivities of cell culture cytotoxin detection and EIA toxin tests range from 67%
to 100% and 63% to 99%, respectively.9 Clinical and laboratory
criteria for assessment of C. difﬁcile did vary across the Prevention Epicenter hospitals. We cannot assess whether these
differences had an appreciable impact on CDAD rates.
Second, the case deﬁnition for healthcare-associated
CDAD for each hospital was unique, particularly regarding
four variables. These include the duration of hospitalization
prior to incident sample collection, the time from previous
hospital discharge until the development of symptoms, and
whether CDAD diagnosed in outpatients was included in surveillance. Moreover, the deﬁnitions of recurrent CDAD and
second incident cases varied substantially. For institutions
with relatively high numbers of readmissions, the deﬁnition
used for differentiation of recurrent CDAD versus incident
CDAD could have a greater impact on the ﬁnal calculation of
incident and healthcare-associated rates. Each of these variables may inﬂuence the rate a given hospital reports and so
may affect evaluation of an infection control program.
Other study limitations include the suboptimal sensitivity and speciﬁcity of the various diagnostic CDAD standalone tests and that most of the Prevention Epicenter hospitals are large, mostly urban, tertiary-care teaching facilities
that may not be representative of hospitals nationally.
The 7 Prevention Epicenter hospitals documented
mean annual healthcare-associated CDAD rates of 12.1
cases per 10,000 patient-days and 7.4 cases per 1,000 admissions, with wide but stable variations between sites. The
deﬁnitions of healthcare-associated disease used by the
participating facilities varied considerably. Inherent subtleties are involved in the interpretation and comparison of
infection rates across institutions (eg, patient case mix and
potential ascertainment bias of more intensive surveillance
programs). The variations in operational case classiﬁcation
outlined here only further hinder the efforts to interpret
interinstitutional rate differences and preclude the establishment of a meaningful national benchmark. There is no
standard case deﬁnition of healthcare-associated CDAD
in the published guidelines.9-11 We recommend that one
be developed and that diagnostic tests and testing criteria
be standardized to allow meaningful comparisons between
hospitals. We also invite other medical centers to report
healthcare-associated CDAD rates so that an expected annual rate of CDAD can be better deﬁned.
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TABLE 3
IMPACT OF DIFFERENT DEFINITIONS OF HEALTHCAREASSOCIATED CLOSTRIDIUM DIFFICILE–ASSOCIATED DIARRHEA
ON CASE RATES

No. of
Cases

Rate per
10,000
PatientDays

A = specimen  72 h after admission

225

8.67

B = A + specimen < 72 h after admission with hospitalization in previous 14
d (n = 32)

257

9.91

C = A + specimen < 72 h after admission with hospitalization in previous 30
d (n = 46)

271

10.45

D = specimen  48 h after admission

267

10.29

E = D + specimen < 48 h after admission with hospitalization in previous 14
d (n = 20)

287

11.06*

F = D + specimen < 48 h after admission with hospitalization in previous
30 d (n = 7)

294

11.33†

Deﬁnition of HealthcareAssociated CDAD

CDAD = C. difﬁcile–associated diarrhea.
*Incidence rate ratioA:E = 1.28 (95% conﬁdence interval [CI95], 1.07–1.52).
†
Incidence rate ratioA:F = 1.31 (CI95, 1.10–1.54).
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